Dr Reddys Laboratories Ltd's Q4FY25 Quarter Results
- 4d ago
Result Summary
- Dr Reddys Laboratories Ltd reported a 14.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 13.3%.
- Its expenses for the quarter were down by 14.0% QoQ and up 12.8% YoY.
- The net profit decreased 6.7% QoQ and increased 36.4% YoY.
- The earnings per share (EPS) of Dr Reddys Laboratories Ltd stood at 78.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 7311.30 | 8531.40 | 6453.70 | -14.3% | 13.3% |
Total Expenses | 5726.90 | 6661.30 | 5078.20 | -14.0% | 12.8% |
Profit Before Tax | 1601.70 | 1870.10 | 1321.50 | -14.4% | 21.2% |
Tax | 295.40 | 470.10 | 369.00 | -37.2% | -19.9% |
Profit After Tax | 1309.80 | 1404.20 | 960.10 | -6.7% | 36.4% |
Earnings Per Share | 78.50 | 16.90 | 57.70 | 364.5% | 36.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dr. Reddy's Laboratories Ltd is a prominent pharmaceutical company based in India, known for its high-quality generic medications, active pharmaceutical ingredients (APIs), and proprietary products. The company operates in the pharmaceutical industry, contributing significantly to the healthcare sector by providing affordable and innovative medicines. Dr. Reddy's Laboratories has a global presence, with facilities and offices spread across various countries. The company continues to focus on expanding its product portfolio, enhancing its research and development capabilities, and strengthening its reach in both emerging and developed markets. Recent developments include strategic collaborations and product launches aimed at enhancing its competitive positioning in key markets.
Revenue
During Q4FY25, Dr. Reddy's Laboratories reported a total income of ₹7311.30 crores. This marks a decrease of 14.3% from the previous quarter (Q3FY25), where the total income was ₹8531.40 crores. However, compared to the same quarter in the previous year (Q4FY24), there was an increase of 13.3%, as the total income then was ₹6453.70 crores. The year-over-year growth indicates a positive trend over the year, despite a decline in quarterly revenue. The fluctuations in revenue may be attributed to various factors, including market demand, product launches, and pricing strategies.
Profitability
The company's profitability metrics for Q4FY25 show a profit before tax of ₹1601.70 crores, reflecting a 14.4% decrease from ₹1870.10 crores in Q3FY25. Year-over-year, there is a growth of 21.2% from ₹1321.50 crores in Q4FY24. The profit after tax for Q4FY25 is ₹1309.80 crores, which is a 6.7% decrease from the previous quarter but a significant 36.4% increase from the same quarter last year. The tax expense for Q4FY25 was ₹295.40 crores, which declined by 37.2% compared to Q3FY25 and by 19.9% year-over-year. These figures indicate changes in profitability due to various internal and external factors affecting the company's financial performance.
Operating Metrics
In the fourth quarter of fiscal year 2025, Dr. Reddy's Laboratories reported an earnings per share (EPS) of ₹78.50. This is a substantial increase from ₹16.90 in the previous quarter, marking a quarter-over-quarter growth of 364.5%. Compared to Q4FY24, where the EPS was ₹57.70, there is a year-over-year increase of 36.0%. These shifts in EPS are indicative of the company's operational performance and shareholder value. Total expenses for Q4FY25 amounted to ₹5726.90 crores, a decrease of 14.0% from ₹6661.30 crores in Q3FY25, and a 12.8% increase from ₹5078.20 crores in Q4FY24. These expense trends are essential for understanding the company's cost management and operational efficiency.
